← Back to Search

Multidisciplinary Care for Heart Failure and Kidney Disease

Q: How many participants are being recruited for the trial?

<p>Affirmative. Information displayed on clinicaltrials.gov reveals that this study, initially published in June 2022 and updated as recent as September of the same year, is currently seeking volunteers to participate. The research requires 160 individuals from one location to complete it's enrollment goals.</p>

Q: Are any new participants being admitted for the trial?

<p>Affirmative, the details found on clinicaltrials.gov confirm that this research is actively searching for participants. This investigation was posted to the website on June 1st 2022 and has been edited as recently as September 8th of the same year. The study requires 160 patients from a single site in order to proceed with their work.</p>

N/A

Waitlist Available

Led By Janai Rangaswami, MD

Research Sponsored by George Washington University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 years of age or older

History of HF with reduced ejection fraction (HFrEF) or ejection fraction (EF) <50% and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) < 60cc/min/1.73m2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial plans to create a new, virtual cardio-renal multidisciplinary team to ease the coordination of care for heart failure and chronic kidney disease patients, who often don't receive the appropriate medication due to the current health care delivery model.

Who is the study for?

This trial is for adults over 18 with heart failure (HF) where the heart's pumping power is reduced (ejection fraction <50%) and also have chronic kidney disease (CKD) with a filtration rate of less than 60cc/min. It excludes those under 18, transplant recipients, dialysis patients, pregnant women, non-English speakers, and anyone unable to understand the study.Check my eligibility

What is being tested?

The trial tests a new virtual care coordination team approach for managing HF and CKD patients. This includes specialists in both fields working together to improve medication management compared to traditional referral-based methods.See study design

What are the potential side effects?

Since this trial focuses on care coordination rather than a specific drug or medical procedure, there are no direct side effects from interventions being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have heart failure with an ejection fraction under 50% and chronic kidney disease.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Difference in rate of sodium glucose co-transporter 2 inhibitors (SGLT2i)

Secondary outcome measures

Heart failure hospitalizations

Cardiomyopathies

Disease

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: InterventionExperimental Treatment1 Intervention

Patients randomized based on their primary care clinician to a co-localized care with a telemedicine-based cardiorenal multidisciplinary team (cardiologist, nephrologist, and research coordinators) providing guidance and recommendations to the primary care clinician.

Group II: ControlActive Control1 Intervention

Patients randomized to the control group will proceed with usual care with a primary care clinician making referrals to a cardiologist or nephrologist "for-cause" as determined by the primary care clinician, to ultimately assess the rates of improvement in the implementation of GDMT.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

George Washington UniversityLead Sponsor

243 Previous Clinical Trials

453,678 Total Patients Enrolled

Janai Rangaswami, MDPrincipal InvestigatorFellowship program director for the Division of Nephrology, Director of the cardiorenal program

Media Library

Multidisciplinary Care Coordination Team Clinical Trial Eligibility Overview. Trial Name: NCT05531214 — N/A

Heart Failure Research Study Groups: Intervention, Control

Heart Failure Clinical Trial 2023: Multidisciplinary Care Coordination Team Highlights & Side Effects. Trial Name: NCT05531214 — N/A

Multidisciplinary Care Coordination Team 2023 Treatment Timeline for Medical Study. Trial Name: NCT05531214 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being recruited for the trial?

"Affirmative. Information displayed on clinicaltrials.gov reveals that this study, initially published in June 2022 and updated as recent as September of the same year, is currently seeking volunteers to participate. The research requires 160 individuals from one location to complete it's enrollment goals."

Answered by AI

Are any new participants being admitted for the trial?

"Affirmative, the details found on clinicaltrials.gov confirm that this research is actively searching for participants. This investigation was posted to the website on June 1st 2022 and has been edited as recently as September 8th of the same year. The study requires 160 patients from a single site in order to proceed with their work."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Creating A Cardiorenal Multidisciplinary Team for Management HF and CKD Patients

Gurusher Panjrath 2022. "Creating A Cardiorenal Multidisciplinary Team for Management HF and CKD Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05531214.